Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Department of Life Sciences and Zlotowski Centre for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel; 2 Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA; 3 Pacific Institute of Medical Research, Los Angeles, CA, USA; 4 Alivation Health, Lincoln, NE, USA; 5 Beer-Sheva Mental Health Center, Ministry of Health, Beer-Sheva, Israel; 6 Lindner Center of HOPE, and University of Cincinnati Department of Psychiatry and Behavioral Medicine, Cincinnati, OH, USA; 7 Tel Aviv University Medical School, Tel Aviv and Be’er Yaacov Mental Health Center, Be’er Yaacov, Israel; 8 Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL, USA; 9 Advanced Mental Health Care Inc., Royal Palm Beach, FL, USA; 10Kadima Neuropsychiatry Institute, La Jolla, CA, USA; 11Harvard Medical School, McLean Hospital, Belmont, MA, USA; 12New York University School of Medicine and Nathan Kline Institute, New York, NY, USA; 13Senior Adults Specialty Research, Austin, TX, USA; 14TMS Center of Colorado, Lakewood, CO, USA; 15A. Stein – Regulatory Affairs Consulting Ltd., Kfar Saba, Israel; 16Biostatistical Consulting, BioStats, Modiin-Maccabim-Reut, Israel; 17Brain Stimulation Division, Psychiatry, Medical University of South Carolina, Charleston, SC, USA; 18Ralph H. Johnson VA Medical Center, Charleston, SC, USA
Список исп. литературыСкрыть список 1. Ziemann U.Thirty years of transcranial magnetic stimulation: where do we stand? Exp Brain Res 2017;235:973-84. 2. Roth Y, Zangen A, Hallett M. A coil design for transcranial magnetic stimulation of deep brain regions. J Clin Neurophysiol 2002;19:361-70. 3. Carmi L, Tendler A, Bystritsky A et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. Am J Psychiatry 2019;176:931-8. 4. Levkovitz Y, Isserles M, Padberg F et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry 2015;14:64-73. 5. O’Reardon JP, SolVASon HB, Janicak PG et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62:1208-16. 6. Uhl GR, Koob GF, Cable J. The neurobiology of addiction. Ann NY Acad Sci 2019;1451:5-28. 7. Gowing LR, Ali RL, Allsop S et al. Global statistics on addictive behaviours: 2014 status report. Addiction 2015;110:904-19. 8. American Psychiatric Association . Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013. [Google Scholar] 9. Halpern SD, Harhay MO, Saulsgiver K et al. A pragmatic trial of e-cigarettes, incentives, and drugs for smoking cessation. N Engl J Med 2018;378:2302-10. 10. Benowitz NL. Nicotine addiction. N Engl J Med 2010;362:2295-303. 11. Goodchild M, Nargis N, d’Espaignet ET. Global economic cost of smoking-attributable diseases. Tob Control 2018;27:58-64. 12. Amiaz R, Levy D, Vainiger D et al. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. Addiction 2009;104:653-60. 13. Eichhammer P, Johann M, Kharraz A et al. High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. J Clin Psychiatry 2003;64:951-3. 14. Levy D, Shabat-Simon M, Shalev U et al. Repeated electrical stimulation of reward-related brain regions affects cocaine but not “natural” reinforcement. J. Neurosci 2007;27:14179-89. 15. Li X, Hartwell KJ, Owens M et al. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex reduces nicotine cue craving. Biol Psychiatry 2013;73:714-20. 16. Wing VC, Bacher I, Wu BS et al. High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophr Res 2012;1:264-6. 17. Strafella AP, Paus T, Barrett J et al. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 2001;21:RC157. 18. Zangen A, Hyodo K. Transcranial magnetic stimulation induces increases in extracellular levels of dopamine and glutamate in the nucleus accumbens. Neuroreport 2002;13:2401-5. 19. Dinur-Klein L, Dannon P, Hadar A et al. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry 2014;76:742-9. 20. Hauer L, Scarano GI, Brigo F et al. Effects of repetitive transcranial magnetic stimulation on nicotine consumption and craving: a systematic review. Psychiatry Res 2019;281:112562. 21. Ekhtiari H, Tavakoli H, Addolorato G et al. Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead. Neurosci Biobehav Rev 2019;104:118-40. 22. Keel JC, Smith MJ, Wassermann EM. A safety screening questionnaire for transcranial magnetic stimulation. Clin Neurophysiol 2001;112:720. 23. Heishman SJ, Singleton EG, Moolchan ET. Tobacco Craving Questionnaire: reliability and validity of a new multifactorial instrument. Nicotine Tob Res 2003;5:645-54. 24. Heatherton TF, Kozlowski LT, Frecker RC et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-27. 25. Bramer SL, Kallungal BA. Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers 2003;8:187-203. 26. Schick SF, Blount BC, Jacob P 3rd et al. Biomarkers of exposure to new and emerging tobacco delivery products. Am J Physiol Lung Cell Mol Physiol 2017;313:L425-52. 27. Hughes JR. Tobacco withdrawal in self-quITTers. J Consult Clin Psychol 1992;60:689-97 28. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98. 29. Buschke H.Selective reminding for analysis of memory and learning. J Verb Learning Verb Behav 1973;12:543-50. [Google Scholar] 30. Fiocchi S, Chiaramello E, Luzi L et al. Deep transcranial magnetic stimulation for the addiction treatment: electric field distribution modeling. IEEE J Electromagn RF Microw Med Biol 2018;2:242-8. [Google Scholar] 31. National Cancer Institute. Clearing the air. https://www.cancer.gov. 32. Gonzales D, Rennard S, Nides M et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA 2006;296:47-55. 33. Hurt RD, Sachs DP, Glover ED et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202. 34. Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91. 35. Tashkin D, Kanner R, Bailey W et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357:1571-5. 36. Lefaucheur J-P, André-Obadia N, Antal A et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014;125:2150-206. 37. Zibman S, Pell GS, Barnea-Ygael N et al. Application of transcranial magnetic stimulation for major depression: coil design and neuroanatomical variability considerations. Eur Neuropsychopharmacol 2021;45:73-88. 38. Food and Drug Administration. FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings. https://www.fda.gov. 39. Tendler A, Sisko E, Barnea-Ygael N et al. A method to provoke obsessive compulsive symptoms for basic research and clinical interventions. Front Psychiatry 2019;10:814. 40. Moran LV, Stoeckel LE, Wang K et al. Nicotine increases activation to anticipatory valence cues in anterior insula and striatum. Nicotine Tob Res 2018;20:851-8. 41. Janes AC, Nickerson LD, Frederick BD et al. Prefrontal and limbic resting state brain network functional connectivity differs between nicotine-dependent smokers and non-smoking controls. Drug Alcohol Depend 2012;125:252-9. 42. Versace F, Engelmann JM, Jackson EF et al. Do brain responses to emotional images and cigarette cues differ? An fMRI study in smokers. Eur J Neurosci 2011;34:2054-63.